

# Life Sciences CLE Day Agenda for Philadelphia and Pittsburgh Sessions

# Agenda | Thursday, November 15, 2018

**Reed Smith Philadelphia:** Three Logan Square, 1717 Arch Street, 31st floor, Philadelphia, PA 19103

**Reed Smith Pittsburgh:** 225 Fifth Avenue, Pittsburgh, PA, 15222

Our morning sessions focus on product liability, while our afternoon sessions have more of a regulatory angle. You are welcome to register for the Life Sciences CLE Day and attend either the entire day or just those sessions of most interest to you.

9:00 a.m. – 9:30 a.m.

## Registration, Networking & Breakfast

9:30 a.m. – 10:30 a.m.

## Session 1: Games Plaintiff's Attorneys Play: Questionable Ethics and Sanctionable Conduct

In this Ethics CLE program, nationally-recognized trial lawyers Barbara Binis and Michael Scott will share stories of the questionable ethics and sanctionable conduct they have seen over their careers from plaintiff's lawyers, and will discuss the "do's and don't's" in-house counsel can learn from these experiences.

### Presenters:

- **Barbara Binis**, partner
- **Michael Scott**, senior counsel

10:30 a.m. – 11:00 a.m.

## Session 2: Games Experts Play (And How to Beat Them)

This presentation will discuss the recent New Jersey Supreme Court decision in *In re Accutane Litigation*, No. A-25-17, (N.J. Aug. 1, 2018), where the Court unanimously upgraded the state's standards for admission of expert testimony. We will also cover the Daubert/Frye distinction, focusing on how this necessarily affects the related presentation and challenges to expert testimony in the relevant jurisdictions. This presentation will also highlight recent examples of litigations where defendants have successfully used Daubert motion practice to exclude plaintiffs' expert witnesses resulting in the ultimate dismissal of litigation.

### Presenters:

- **George McDavid**, partner
- **Shana Russo**, counsel
- **Jennifer Eppensteiner**, associate

11:00 a.m. – 11:15 a.m.

## Break

11:15 a.m. – 12:15 p.m.

### Session 3: Games People Play: Decision Points in MDLs

The panel will examine recent trends in multidistrict litigation, particularly in life sciences and product liability cases. The focus will be on strategies for being in the right court, reasonably cabinning the scope of discovery, facilitating federal-state and joint defense cooperation, and avoiding adverse trial scenarios.

**Presenters:**

- **Steve McConnell**, partner
- **Rachel Weil**, counsel
- **Whitney Mayer**, associate

12:15 p.m. – 12:45 p.m.

### Session 4: Key Issues Currently Before the Supreme Court and Other Supremely Interesting Cases

Teed up for the current Supreme Court term are several cases with significant implications for preemption in prescription drug cases, class action strike suits, and even basic product liability law. Jim will discuss their ramifications. In addition Jim will discuss recent interesting developments in several other appellate courts.

**Presenters:**

- **Jim Beck**, senior life sciences policy analyst
- **Lora Spencer**, associate

12:45 p.m. – 1:15 p.m.

### Buffet Lunch

1:15 p.m. – 2:15 p.m.

### Session 5: Looking Around the Corner: Health Tech Developments Affecting Drug and Device Companies

This session will discuss the legal implications for pharmaceutical and medical device companies of several key technologies: pharmacogenomics, 3D printing, artificial intelligence, blockchain, and digital health.

**Presenters:**

- **Kim Gold**, partner
- **Gerry Stegmaier**, partner
- **Matt Jacobson**, associate
- **Andrew Lu**, associate

2:15 p.m. – 2:45 p.m.

### Session 6: Tell Me Something I Don't Already Know About GDPR

In this session, Reed Smith lawyers who counsel pharmaceutical, medical device, and digital health companies on data privacy and security issues will speak about some of the unexpected issues their clients have seen in a post-GDPR world despite careful preparedness for GDPR implementation. They will also touch on how the requirements of new local laws are affecting life sciences companies, including in the context of clinical research and potential conflicts with GDPR.

**Presenters:**

- **Kim Gold**, partner
- **Sam Cullari**, counsel

2:45 p.m. – 3:00 p.m.

## Break

3:00 p.m. – 3:30 p.m.

### Session 7: What Are State Attorney Generals Up to Now?

For decades, State AGs have had a significant – some would say leading -- role in regulating and initiating enforcement actions against life sciences companies and members of the health care industry. This presentation highlights the key enforcement activities by AGs relevant to these industries. Also, with at least a dozen new AGs taking office in 2019, it identifies likely new trends of which entities in these areas should be aware.

#### Presenter:

- **Divonne Smoyer**, partner

3:30 p.m. – 4:30 p.m.

### Session 8: Pharmaceutical Pricing and Contracting Compliance: I Never Promised You a Rose Garden

The Trump Administration's May 2018 announcement of a "Blueprint" to address concerns over pharmaceutical pricing made clear that virtually every level of price-related concession or relationship within the existing drug distribution paradigm could be subject to new forms of regulation. This session will:

- Include an overview of the underlying compliance policy concerns affecting pharmaceutical pricing and contracting;
- Review existing and emerging price regulation schemes and how the "Blueprint" may affect them;
- Provide a "taxonomy" for regulatory analysis of patient copay support and patient assistance programs and discuss the future of such programs in light of recent enforcement and potential broader changes within the pricing environment; and
- Update attendees on new guidance and regulatory compliance initiatives surrounding value- and outcomes-based pricing arrangements

#### Presenter:

- **Joe Metro**, partner


4:30 p.m. – 5:30 p.m.

### Networking Reception

(Currently Philadelphia only)

**Reed Smith is a dynamic international law firm, dedicated to helping clients move their businesses forward.**

Our long-standing relationships, international outlook and collaborative structure make us the go-to partner for speedy resolution of complex disputes, transactions and regulatory matters.



“Reed Smith” refers to Reed Smith LLP and related entities. © Reed Smith LLP 2018

- ABU DHABI
- ATHENS
- AUSTIN
- BEIJING
- CENTURY CITY
- CHICAGO
- DUBAI
- FRANKFURT
- HONG KONG
- HOUSTON
- KAZAKHSTAN
- LONDON
- LOS ANGELES
- MIAMI
- MUNICH
- NEW YORK
- PARIS
- PHILADELPHIA
- PITTSBURGH
- PRINCETON
- RICHMOND
- SAN FRANCISCO
- SHANGHAI
- SILICON VALLEY
- SINGAPORE
- TYSONS
- WASHINGTON, D.C.
- WILMINGTON

**reedsmith.com**